Abstract
Malaria Vaccines: Progressing on a Bumpy Road
Highlights
Malaria remains the most prevalent parasitic infection in the world
Valuable progress has been achieved in the last 30 years in the development of P. falciparum subunit vaccines (Greenwood and Targett, 2011; Schwartz et al, 2012) that could be included in the Expanded Program of Immunization (EPI)
The most advanced malaria vaccine candidate, the RTS,S vaccine based on the P. falciparum circumsporozoite (CS) protein, has gone through extensive testing in Africa where a recent phase 3 trial showed a 27 and 46% protection against clinical malaria in African infant and children respectively but its efficacy wanes down in a relatively short time (The RTS, S Clinical Trials Partnership, 2014)
Summary
Malaria remains the most prevalent parasitic infection in the world. Up to 40% of the world population is estimated to be at risk of contracting malaria. The development of a malaria vaccine is considered as one of the most cost-effective measures to counter the disease. Valuable progress has been achieved in the last 30 years in the development of P. falciparum subunit vaccines (Greenwood and Targett, 2011; Schwartz et al, 2012) that could be included in the Expanded Program of Immunization (EPI),
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
